A Phase 3 interventional study of ABP 938 and Aflibercept in Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Amgen. Completed at 118 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 18 in phase 3, and was the 46th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 2 started in 2020.
This study's enrollment of 576 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.
Approximately 566 subjects will be randomized in approximately 126 global sites.
This study consists of a screening period of up to 4 weeks, after which subjects will receive investigational product for 48 weeks, followed by a safety follow-up period to week 52, for a total study duration of up to 56 weeks.
Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by IVT injection.
At week 8, subjects will be assessed for the primary endpoint. The primary endpoint is the change in Best Corrected Visual Acuity (BCVA) as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score from baseline to week 8, in order to assess the efficacy of ABP 938 compared to aflibercept.
Subjects will then be re-randomized at week 16 in a masked fashion such that:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects are excluded if they meet any of the following criteria in the study eye:
Subjects are excluded if they meet any of the following criteria in either eye:
Other Medical Conditions
Washouts and Nonpermitted Treatments
General
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.
Drug: ABP 938
Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48.
Drug: Aflibercept
Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
Drug: ABP 938 · Drug: Aflibercept
Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks
Also known as: Eylea®
Mean Change From Baseline in BCVA at Week 8
BCVA score was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.
Time frame: Baseline and Week 8
Percentage of Participants Who Maintained Vision at Week 52
A participant was classified as maintaining vision if he/she lost fewer than 15 letters in ETDRS letter score, assessed in the study eye, compared to Baseline.
Time frame: Week 52
Mean Change From Baseline in BCVA
BCVA score was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.
Time frame: Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52
Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8
Percentage of participants who gained at least 10 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.
Time frame: Week 8
Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52
Percentage of participants who gained at least 15 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.
Time frame: Week 52
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size
CNV area size was measured by fluorescein angiography. Change from Baseline calculated as observed post-baseline value - Baseline value.
Time frame: Baseline and Weeks 8, 16, 24, and 52
Mean Change From Baseline in Central Subfield Thickness (CST)
CST was defined as the average thickness in the ETDRS central 1 mm diameter subfield (the central subfield) and was measured by spectral domain optical coherence tomography. Change from Baseline calculated as observed post-baseline value - Baseline value.
Time frame: Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant. TEAEs were defined as those AEs that begin or increase in severity or frequency at or after the time of first treatment to the End of Study visit. Events of interest (EOIs) pre-specified for this study included endophthalmitis, retinal detachment, increase in intraocular pressure, and thromboembolic events. Serious AEs were defined as any untoward medical occurrence that meets at least 1 of the following serious criteria: * Results in death * Life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important serious event.
Time frame: Up to Week 52
Number of Participants Developing Binding Antidrug Antibodies (ADAs)
Number of participants with positive post-baseline ADA result through Week 16 and post Week 16 with negative or no result at Baseline is reported.
Time frame: Baseline up to Week 52
This study was conducted at 102 centers in Canada, Czech Republic, Estonia, Germany, Hong Kong, Hungary, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Poland, Slovakia, Spain, and the United States between 22 June 2020 and 30 January 2023.
| Milestone | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Started | 288 | 288 | 0 |
| Completed | 273 | 270 | 0 |
| Not completed | 15 | 18 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Consent withdrawn | 3 | 3 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
| Withdrew: Protocol specified criteria | 6 | 7 | 0 |
| Withdrew: Miscellaneous | 1 | 1 | 0 |
| Milestone | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Started | 273 | 136 | 134 |
| Received treatment | 273 | 136 | 133 |
| Completed | 251 | 125 | 123 |
| Not completed | 22 | 11 | 11 |
| Withdrew: Adverse event | 7 | 5 | 1 |
| Withdrew: Death | 2 | 0 | 2 |
| Withdrew: Consent withdrawn | 4 | 3 | 6 |
| Withdrew: Physician decision | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Requirement for alternative therapy | 1 | 0 | 0 |
| Withdrew: Requirement for alternative dosing schedule | 2 | 1 | 0 |
| Withdrew: Miscellaneous | 1 | 0 | 1 |
BCVA score was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.
| Letters | ABP 938 | Aflibercept |
|---|---|---|
| Mean Change From Baseline in BCVA at Week 8 | 6.4 ± 8.18 | 6.5 ± 8.97 |
A participant was classified as maintaining vision if he/she lost fewer than 15 letters in ETDRS letter score, assessed in the study eye, compared to Baseline.
| Percentage of Participants | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Percentage of Participants Who Maintained Vision at Week 52 | 95.6 (93.1 to 98.2) | 97.6 (94.9 to 100.0) | 95.9 (92.5 to 99.4) |
BCVA score was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.
| Letters | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Week 4 | 5.0 ± 6.57 | 5.4 ± 8.35 | 3.8 ± 8.19 |
| Week 8 | 6.5 ± 8.10 | 7.6 ± 9.30 | 5.6 ± 8.86 |
| Week 16 | 6.8 ± 8.69 | 7.5 ± 9.31 | 7.1 ± 9.32 |
| Week 24 | 7.2 ± 9.63 | 7.1 ± 9.30 | 7.0 ± 10.12 |
| Week 32 | 7.1 ± 11.00 | 8.7 ± 9.21 | 6.6 ± 11.11 |
| Week 40 | 7.3 ± 11.00 | 8.1 ± 11.00 | 7.9 ± 10.08 |
| Week 48 | 7.2 ± 11.51 | 8.7 ± 10.84 | 8.1 ± 10.74 |
| Week 52 | 7.6 ± 11.60 | 9.4 ± 10.18 | 8.0 ± 11.14 |
Percentage of participants who gained at least 10 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.
| Percentage of participants | ABP 938 | Aflibercept |
|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8 | 29.4 (24.1 to 34.7) | 32.7 (27.3 to 38.2) |
Percentage of participants who gained at least 15 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.
| Percentage of participants | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52 | 24.3 (19.0 to 29.6) | 29.6 (21.6 to 37.6) | 24.4 (16.8 to 32.0) |
CNV area size was measured by fluorescein angiography. Change from Baseline calculated as observed post-baseline value - Baseline value.
| mm^2 | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Week 8 | -4.962 ± 5.1604 | -5.479 ± 5.1023 | -5.169 ± 4.6943 |
| Week 16 | -4.089 ± 5.3668 | -5.174 ± 5.2280 | -4.751 ± 4.8814 |
| Week 24 | -4.323 ± 5.5972 | -5.308 ± 5.6238 | -5.121 ± 5.2776 |
| Week 52 | -6.276 ± 6.2690 | -7.280 ± 5.8262 | -6.434 ± 5.2445 |
CST was defined as the average thickness in the ETDRS central 1 mm diameter subfield (the central subfield) and was measured by spectral domain optical coherence tomography. Change from Baseline calculated as observed post-baseline value - Baseline value.
| μm | ABP 938 / ABP 938 | Aflibercept / Aflibercept | Aflibercept / ABP 938 |
|---|---|---|---|
| Week 4 | -136.5 ± 108.91 | -143.1 ± 107.32 | -149.7 ± 107.01 |
| Week 8 | -145.9 ± 106.24 | -146.3 ± 110.39 | -167.4 ± 118.52 |
| Week 16 | -125.2 ± 124.81 | -127.3 ± 103.35 | -143.2 ± 121.93 |
| Week 24 | -130.8 ± 125.63 | -131.7 ± 102.98 | -151.2 ± 118.21 |
| Week 32 | -133.2 ± 122.93 | -134.1 ± 116.02 | -154.8 ± 114.22 |
| Week 40 | -132.3 ± 113.25 | -135.6 ± 119.07 | -155.7 ± 119.95 |
| Week 48 | -132.3 ± 124.15 | -141.1 ± 112.29 | -157.8 ± 121.23 |
| Week 52 | -157.1 ± 114.25 | -159.1 ± 108.82 | -177.4 ± 122.22 |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant. TEAEs were defined as those AEs that begin or increase in severity or frequency at or after the time of first treatment to the End of Study visit. Events of interest (EOIs) pre-specified for this study included endophthalmitis, retinal detachment, increase in intraocular pressure, and thromboembolic events. Serious AEs were defined as any untoward medical occurrence that meets at least 1 of the following serious criteria: * Results in death * Life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important serious event.
| Participants | Through Week 16: ABP 938 | Through Week 16: Aflibercept | Post Week 16: ABP 938 / ABP 938 | Post Week 16: Aflibercept / ABP 938 | Post Week 16: Aflibercept / Aflibercept |
|---|---|---|---|---|---|
| Any TEAEs | 113 | 107 | 144 | 76 | 72 |
| Any EOIs | 6 | 3 | 9 | 8 | 2 |
| Any Serious TEAEs | 6 | 9 | 22 | 14 | 11 |
Number of participants with positive post-baseline ADA result through Week 16 and post Week 16 with negative or no result at Baseline is reported.
| Participants | Through Week 16: ABP 938 | Through Week 16: Aflibercept | Post Week 16: ABP 938 / ABP 938 | Post Week 16: Aflibercept / ABP 938 | Post Week 16: Aflibercept / Aflibercept |
|---|---|---|---|---|---|
| Number of Participants Developing Binding Antidrug Antibodies (ADAs) | 1 | 4 | 4 | 3 | 0 |
Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Through Week 16: ABP 938 | 0/288 (0%) | 6/288 (2.1%) | 18/288 (6.3%) |
| Through Week 16: Aflibercept | 2/288 (0.7%) | 9/288 (3.1%) | 15/288 (5.2%) |
| Post Week 16: ABP 938 / ABP 938 | 2/273 (0.7%) | 22/273 (8.1%) | 20/273 (7.3%) |
| Post Week 16: Aflibercept / ABP 938 | 2/133 (1.5%) | 14/133 (10.5%) | 17/133 (12.8%) |
| Post Week 16: Aflibercept / Aflibercept | 0/136 (0%) | 11/136 (8.1%) | 17/136 (12.5%) |
| Event | Through Week 16: ABP 938 | Through Week 16: Aflibercept | Post Week 16: ABP 938 / ABP 938 | Post Week 16: Aflibercept / ABP 938 | Post Week 16: Aflibercept / Aflibercept |
|---|---|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/288 | 0/288 | 2/273 | 3/133 | 0/136 |
| Femur fractureInjury, poisoning and procedural complications | 1/288 | 0/288 | 3/273 | 0/133 | 0/136 |
| Acute myocardial infarctionCardiac disorders | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| Cardiac failure congestiveCardiac disorders | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| AppendicitisInfections and infestations | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| PneumoniaInfections and infestations | 0/288 | 1/288 | 1/273 | 1/133 | 0/136 |
| ContusionInjury, poisoning and procedural complications | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| FallInjury, poisoning and procedural complications | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| Rib fractureInjury, poisoning and procedural complications | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| Heart rate decreasedInvestigations | 0/288 | 0/288 | 0/273 | 1/133 | 0/136 |
| Event | Through Week 16: ABP 938 | Through Week 16: Aflibercept | Post Week 16: ABP 938 / ABP 938 | Post Week 16: Aflibercept / ABP 938 | Post Week 16: Aflibercept / Aflibercept |
|---|---|---|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 6/288 | 4/288 | 16/273 | 10/133 | 11/136 |
| Conjunctival haemorrhageEye disorders | 12/288 | 11/288 | 4/273 | 8/133 | 8/136 |
Full Analysis Set: Consisted of all randomized participants, with treatment as the randomized treatment regardless of actual treatment received. Participants were included in the treatment group in which they were initially randomized.
| Age, Continuous(Years) | ABP 938 | Aflibercept | Total |
|---|---|---|---|
| Mean | 76.0 ± 7.93 | 76.0 ± 7.95 | 76.0 ± 7.93 |
| Sex: Female, Male(Participants) | ABP 938 | Aflibercept | Total |
|---|---|---|---|
| Female | 151 | 171 | 322 |
| Male | 137 | 117 | 254 |
| Ethnicity (NIH/OMB)(Participants) | ABP 938 | Aflibercept | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 13 | 19 |
| Not Hispanic or Latino | 281 | 275 | 556 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | ABP 938 | Aflibercept | Total |
|---|---|---|---|
| Asian | 36 | 39 | 75 |
| Black or African American | 1 | 1 | 2 |
| Multiple | 1 | 0 | 1 |
| White | 250 | 248 | 498 |
Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Jul 2022, 24 months.
Results were first posted in Jan 2024, 1 year 5 months after primary completion. A results delay was requested in May 2023.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept